Lannett works with China partner on insulin generic
PHILADELPHIA — Lannett Co. plans to co-develop a generic insulin pharmaceutical product for the U.S. market with YiChang HEC ChangJiang Pharmaceutical Co. Ltd., its strategic partner in China. Lannett said Friday that holds the exclusive U.S. marketing rights to the product, which currently is in late-stage development. The company will manage the remaining clinical and
